Doctor of Philosophy, Case Western Reserve University, 2015, Molecular Medicine
The epidermal growth factor receptor (EGFR) drives downstream signaling pathways that promote cancer progression. EGFR is often constitutively active in tumors, e.g., non-small cell lung cancer (NSCLC) and glioblastoma (GBM), either by overexpression or mutations. Nuclear factor-κB (NF-κB) is a master transcription factor that controls inflammation and innate immunity. NF-κB, often constitutively activated in cancer, drives tumor development by activating antiapoptotic and prosurvival genes, and has been implicated in anticancer drug resistance. We and others have shown that EGFR activates NF-κB signaling in both noncancerous and cancer cells. In an attempt to overcome drug resistance to EGFR tyrosine kinase inhibitors (TKI): erlotinib and lapatinib in NSCLC and GBM respectively, we combined EGFR-TKI with a novel class of NF-κB inhibitors, including quinacrine and curaxins, which inhibit NF-κB-driven transcription by targeting the facilitates chromatin transcription (FACT) complex. Unexpectedly, we discovered preferential targeting of GBM stem cells (GSCs), another major player in cancer therapeutic resistance, by curaxins, uncovering a potential role of FACT in the maintenance of stem cell phenotypes. Beyond applications in anticancer therapeutics, we are interested in the basic biological question of how EGFR, compared to canonical NF-κB activators such as interleukin 1 (IL-1), regulates NF-κB distinctively. Specifically, we utilize genomic approaches including RNA-sequencing (RNA-sequencing) and chromatin immunoprecipitation (ChIP)-sequencing to investigate the signal-specific, genome-wide regulation of NF-κB-driven transcription by EGFR versus IL-1. One possible mechanism that underlies specificity in transcription factor regulation is differential phosphorylation. We speculate that phosphorylation of the serine 276 residue on the NF-κB subunit p65 (RELA) plays a role in EGFR-mediated NF-κB regulation. Using the gene editing approach CRISPR, we have introduced t (open full item for complete abstract)
Committee: George Stark PhD (Advisor); Mark Jackson PhD (Committee Chair); Charis Eng MD, PhD (Committee Member); Brian Rubin MD, PhD (Committee Member); Micheala Aldred PhD (Committee Member)
Subjects: Cellular Biology; Genetics; Molecular Biology; Oncology